英国药品和健康产品管理局(MHRA)已批准佐剂三价流感疫苗AUJEMFLU的上市许可,该疫苗旨在为50岁及以上的成年人群提供针对流感的保护。
此次批准为相关公司带来了进一步的市场覆盖机会。
英国药品和健康产品管理局(MHRA)已批准佐剂三价流感疫苗AUJEMFLU的上市许可,该疫苗旨在为50岁及以上的成年人群提供针对流感的保护。
此次批准为相关公司带来了进一步的市场覆盖机会。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.